About the study

To assess early phase safety and tolerability of converting patients from approved oral, injectable or infusion RMS DMTs to siponimod (Mayzent). The results of this study will guide clinically relevant decisions related to the transition from frequently used RMS DMTs to siponimod (Mayzent) and provide clinically relevant data on safety and tolerability for healthcare providers who are considering converting patients from currently approved RMS DMT to siponimod (Mayzent).

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria

1. inclusive) at screening 3. Patients with advancing RMS as defined by the principal investigator 4. Prior history of relapsing MS (RMS), with or without progressive features, according to the 2010 Revised McDonald or Lublin criteria (Lublin et al,
2. 2013) 5. EDSS score of >/= 2.0 to 6.5 (
3. inclusive) 6. Having been continuously treated with oral, injectable or infusion RMS DMTs Key

Exclusion criteria

1. lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test. 2. Patients with any medically unstable condition as determine by the investigator. 3. History of hypersensitivity to the study drug or to drugs of similar chemical classes. Other protocol-defined inclusion/exclusion criteria may apply.

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.